Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug – a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis – may be too good to be true, according to Arthur M. Feldman, MD, PhD, Executive Dean of the Lewis Katz School of Medicine at Temple University, Chief Academic Officer of the Temple University Health System, and Laura H. Carnell Professor of Medicine at LKSOM.
from Dementia Big http://ift.tt/1IWY6o6 via aging memory loss
http://ift.tt/1Q4e1ZE
No comments:
Post a Comment